Organon & Co. OGN
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · organon.com
Organon & Co. is a global healthcare company spun off from Merck & Co. in 2021, focused on improving the health of women throughout their lives. The company markets a portfolio of over 70 products across women's health (contraception, fertility), biosimilars, and established brands in cardiovascular and other therapeutic areas, reaching more than 140 markets worldwide. Headquartered in Jersey City, New Jersey.
Key ratios
FreeCashFlowOnSale TTM 0.09
FreeCashFlowOnSale 2025 0.09
FreeCashFlowOnSale 2024 0.12
FreeCashFlowOnSale 2023 0.09
NetIncomeMargin TTM 0.03
NetIncomeMargin 2025 0.03
NetIncomeMargin 2024 0.13
NetIncomeMargin 2023 0.16
ReturnOnAssets TTM 0.06
ReturnOnAssets 2025 0.06
ReturnOnAssets 2024 0.07
ReturnOnAssets 2023 0.07
ReturnOnEquity TTM 0.31
ReturnOnEquity 2025 0.31
ReturnOnEquity 2024 4.3
Recent news
Organon Canada Announces the Appointment of Dominic Bégin as President and Managing Director
2026-07-22 · Cision/CNW
Organon Secures US Food and Drug Administration Approval Expanding Indications for TOFIDENCE® (tocilizumab-bavi) in Cytokine Release Syndrome (CRS) and Pediatric COVID-19
2026-06-10 · Organon Investor Relations
Sun Pharma signs Definitive Agreement to Acquire Organon
2026-04-26 · Organon Investor Relations